Human papillomavirus types 16 and 18
HPV-16; HPV-18
General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.
Overview
High-risk HPV types that cause most cervical cancers and many anal and oropharyngeal cancers.
Infections
Persistent infection that can progress to precancerous lesions and cancer; genital warts are caused by other (low-risk) types.
Signs and symptoms
Usually none; detected through screening.
Antibiotic and antimicrobial resistance
No antiviral treats HPV, so drug resistance is not relevant. Prevention relies on vaccination and screening.
Treatment considerations
No antiviral treatment; management follows screening and colposcopy guidelines.
Infection control and public health
HPV vaccination prevents infection with these types.

Sources
Sources accessed November 2026. Links open external sites that InnovexLab does not control.
Medical disclaimer
This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.
Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.